Toppgene analysis for Wikipedia protein communities, toppgene analysis, cc271_8, positive side

Go To Start Page
Input Parameters [Show Detail]
Training Results [Expand All] [Download All] [Sparse Matrix]
Display pValues and Scores as Table row limit

1: GO: Molecular Function [Display Chart] 8 input genes in category / 46 annotations before applied cutoff / 18661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0004714 transmembrane receptor protein tyrosine kinase activity 2.446E-6 1.125E-4 4.969E-4 1.125E-4 3 67
2 GO:0019199 transmembrane receptor protein kinase activity 6.172E-6 1.420E-4 6.270E-4 2.839E-4 3 91
3 GO:0004713 protein tyrosine kinase activity 4.930E-5 7.559E-4 3.338E-3 2.268E-3 3 182
4 GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity 3.002E-4 3.453E-3 1.525E-2 1.381E-2 2 62
5 GO:0052813 phosphatidylinositol bisphosphate kinase activity 4.049E-4 3.550E-3 1.568E-2 1.863E-2 2 72
6 GO:0035004 phosphatidylinositol 3-kinase activity 4.631E-4 3.550E-3 1.568E-2 2.130E-2 2 77
7 GO:0004674 protein serine/threonine kinase activity 7.220E-4 4.744E-3 2.095E-2 3.321E-2 3 452
8 GO:0070853 myosin VI binding 8.572E-4 4.929E-3 2.177E-2 3.943E-2 1 2
9 GO:0005006 epidermal growth factor-activated receptor activity 1.286E-3 6.571E-3 2.902E-2
5.914E-2
 1 3
10 GO:0019838 growth factor binding 1.562E-3 7.167E-3 3.165E-2
7.187E-2
 2 142
11 GO:0048408 epidermal growth factor binding 1.714E-3 7.167E-3 3.165E-2
7.884E-2
 1 4
12 GO:0070290 N-acylphosphatidylethanolamine-specific phospholipase D activity 2.142E-3 8.211E-3 3.626E-2
9.853E-2
 1 5
13 GO:0038132 neuregulin binding 2.570E-3 9.093E-3 4.016E-2
1.182E-1
 1 6
14 GO:0004630 phospholipase D activity 2.998E-3 9.849E-3 4.350E-2
1.379E-1
 1 7
15 GO:0005088 Ras guanyl-nucleotide exchange factor activity 4.102E-3 1.230E-2
5.434E-2
1.887E-1
 2 232
16 GO:0030235 nitric-oxide synthase regulator activity 4.280E-3 1.230E-2
5.434E-2
1.969E-1
 1 10
17 GO:0004704 NF-kappaB-inducing kinase activity 5.561E-3 1.505E-2
6.645E-2
2.558E-1
 1 13
18 GO:0005085 guanyl-nucleotide exchange factor activity 7.030E-3 1.797E-2
7.935E-2
3.234E-1
 2 306
19 GO:0004709 MAP kinase kinase kinase activity 1.279E-2 3.097E-2
1.368E-1
5.884E-1
 1 30
20 GO:0005154 epidermal growth factor receptor binding 1.406E-2 3.234E-2
1.429E-1
6.469E-1
 1 33
21 GO:0004864 protein phosphatase inhibitor activity 1.618E-2 3.544E-2
1.565E-1
7.442E-1
 1 38
22 GO:0019212 phosphatase inhibitor activity 1.745E-2 3.648E-2
1.611E-1
8.025E-1
 1 41
Show 17 more annotations

2: GO: Biological Process [Display Chart] 8 input genes in category / 530 annotations before applied cutoff / 18623 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0046777 protein autophosphorylation 1.963E-6 1.040E-3 7.128E-3 1.040E-3 4 245
2 GO:0014066 regulation of phosphatidylinositol 3-kinase signaling 2.785E-5 6.779E-3 4.645E-2 1.476E-2 3 150
3 GO:0014065 phosphatidylinositol 3-kinase signaling 3.837E-5 6.779E-3 4.645E-2 2.034E-2 3 167
4 GO:0048015 phosphatidylinositol-mediated signaling 7.485E-5 8.278E-3
5.671E-2
 3.967E-2 3 209
5 GO:0048017 inositol lipid-mediated signaling 7.809E-5 8.278E-3
5.671E-2
 4.139E-2 3 212
6 GO:0038128 ERBB2 signaling pathway 1.187E-4 1.049E-2
7.184E-2
6.291E-2
 2 39
7 GO:0070372 regulation of ERK1 and ERK2 cascade 1.582E-4 1.198E-2
8.205E-2
8.383E-2
 3 269
8 GO:0070371 ERK1 and ERK2 cascade 1.857E-4 1.230E-2
8.428E-2
9.841E-2
 3 284
9 GO:0006606 protein import into nucleus 2.226E-4 1.284E-2
8.795E-2
1.180E-1
 3 302
10 GO:0006650 glycerophospholipid metabolic process 2.497E-4 1.284E-2
8.795E-2
1.323E-1
 3 314
11 GO:0051170 import into nucleus 2.664E-4 1.284E-2
8.795E-2
1.412E-1
 3 321
12 GO:0017038 protein import 3.465E-4 1.377E-2
9.432E-2
1.836E-1
 3 351
13 GO:0043405 regulation of MAP kinase activity 3.612E-4 1.377E-2
9.432E-2
1.914E-1
 3 356
14 GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling 3.843E-4 1.377E-2
9.432E-2
2.037E-1
 2 70
15 GO:0061026 cardiac muscle tissue regeneration 4.296E-4 1.377E-2
9.432E-2
2.277E-1
 1 1
16 GO:0018108 peptidyl-tyrosine phosphorylation 4.545E-4 1.377E-2
9.432E-2
2.409E-1
 3 385
17 GO:0018212 peptidyl-tyrosine modification 4.614E-4 1.377E-2
9.432E-2
2.445E-1
 3 387
18 GO:0034504 protein localization to nucleus 4.755E-4 1.377E-2
9.432E-2
2.520E-1
 3 391
19 GO:0032388 positive regulation of intracellular transport 4.935E-4 1.377E-2
9.432E-2
2.616E-1
 3 396
20 GO:0046486 glycerolipid metabolic process 5.347E-4 1.417E-2
9.708E-2
2.834E-1
 3 407
21 GO:0006644 phospholipid metabolic process 6.068E-4 1.502E-2
1.029E-1
3.216E-1
 3 425
22 GO:0046854 phosphatidylinositol phosphorylation 6.920E-4 1.502E-2
1.029E-1
3.668E-1
 2 94
23 GO:0030335 positive regulation of cell migration 6.940E-4 1.502E-2
1.029E-1
3.678E-1
 3 445
24 GO:2000147 positive regulation of cell motility 7.547E-4 1.502E-2
1.029E-1
4.000E-1
 3 458
25 GO:0046834 lipid phosphorylation 7.672E-4 1.502E-2
1.029E-1
4.066E-1
 2 99
26 GO:0051272 positive regulation of cellular component movement 8.138E-4 1.502E-2
1.029E-1
4.313E-1
 3 470
27 GO:0040017 positive regulation of locomotion 8.495E-4 1.502E-2
1.029E-1
4.502E-1
 3 477
28 GO:0021551 central nervous system morphogenesis 8.590E-4 1.502E-2
1.029E-1
4.553E-1
 1 2
29 GO:0043006 activation of phospholipase A2 activity by calcium-mediated signaling 8.590E-4 1.502E-2
1.029E-1
4.553E-1
 1 2
30 GO:1902722 positive regulation of prolactin secretion 8.590E-4 1.502E-2
1.029E-1
4.553E-1
 1 2
31 GO:0042307 positive regulation of protein import into nucleus 8.788E-4 1.502E-2
1.029E-1
4.657E-1
 2 106
32 GO:1904591 positive regulation of protein import 9.288E-4 1.511E-2
1.035E-1
4.923E-1
 2 109
33 GO:0006913 nucleocytoplasmic transport 9.406E-4 1.511E-2
1.035E-1
4.985E-1
 3 494
34 GO:0046824 positive regulation of nucleocytoplasmic transport 1.277E-3 1.951E-2
1.336E-1
6.770E-1
 2 128
35 GO:1903800 positive regulation of production of miRNAs involved in gene silencing by miRNA 1.288E-3 1.951E-2
1.336E-1
6.828E-1
 1 3
36 GO:1900182 positive regulation of protein localization to nucleus 1.482E-3 2.183E-2
1.495E-1
7.857E-1
 2 138
37 GO:0032431 activation of phospholipase A2 activity 1.717E-3 2.440E-2
1.671E-1
9.102E-1
 1 4
38 GO:0038127 ERBB signaling pathway 1.771E-3 2.440E-2
1.671E-1
9.387E-1
 2 151
39 GO:0050806 positive regulation of synaptic transmission 1.818E-3 2.440E-2
1.671E-1
9.634E-1
 2 153
40 GO:0007270 neuron-neuron synaptic transmission 1.841E-3 2.440E-2
1.671E-1
9.758E-1
 2 154
41 GO:2001020 regulation of response to DNA damage stimulus 1.889E-3 2.441E-2
1.673E-1
1.000E0
 2 156
42 GO:0043112 receptor metabolic process 2.110E-3 2.645E-2
1.812E-1
1.000E0
 2 165
43 GO:0048143 astrocyte activation 2.146E-3 2.645E-2
1.812E-1
1.000E0
 1 5
44 GO:0050679 positive regulation of epithelial cell proliferation 2.369E-3 2.853E-2
1.955E-1
1.000E0
 2 175
45 GO:0032430 positive regulation of phospholipase A2 activity 2.575E-3 3.033E-2
2.078E-1
1.000E0
 1 6
46 GO:0033002 muscle cell proliferation 2.699E-3 3.074E-2
2.106E-1
1.000E0
 2 187
47 GO:0042306 regulation of protein import into nucleus 2.727E-3 3.074E-2
2.106E-1
1.000E0
 2 188
48 GO:0070374 positive regulation of ERK1 and ERK2 cascade 2.784E-3 3.074E-2
2.106E-1
1.000E0
 2 190
49 GO:1904589 regulation of protein import 2.842E-3 3.074E-2
2.106E-1
1.000E0
 2 192
50 GO:0070459 prolactin secretion 3.004E-3 3.184E-2
2.181E-1
1.000E0
 1 7
Show 45 more annotations

3: GO: Cellular Component [Display Chart] 8 input genes in category / 63 annotations before applied cutoff / 19061 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 GO:0045121 membrane raft 3.025E-4 8.812E-3 4.167E-2 1.906E-2 3 343
2 GO:0098857 membrane microdomain 3.025E-4 8.812E-3 4.167E-2 1.906E-2 3 343
3 GO:0097489 multivesicular body, internal vesicle lumen 4.197E-4 8.812E-3 4.167E-2 2.644E-2 1 1
4 GO:0005901 caveola 6.891E-4 8.812E-3 4.167E-2 4.342E-2 2 96
5 GO:0044853 plasma membrane raft 8.236E-4 8.812E-3 4.167E-2
5.189E-2
 2 105
6 GO:0070435 Shc-EGFR complex 8.393E-4 8.812E-3 4.167E-2
5.287E-2
 1 2
7 GO:0097487 multivesicular body, internal vesicle 1.259E-3 1.133E-2
5.356E-2
7.930E-2
 1 3
8 GO:0016323 basolateral plasma membrane 4.343E-3 3.420E-2
1.617E-1
2.736E-1
 2 244
9 GO:0030122 AP-2 adaptor complex 5.444E-3 3.693E-2
1.746E-1
3.430E-1
 1 13
10 GO:0030128 clathrin coat of endocytic vesicle 5.862E-3 3.693E-2
1.746E-1
3.693E-1
 1 14
11 GO:0005769 early endosome 7.094E-3 3.702E-2
1.750E-1
4.469E-1
 2 314
12 GO:0031253 cell projection membrane 7.902E-3 3.702E-2
1.750E-1
4.978E-1
 2 332
13 GO:0030132 clathrin coat of coated pit 7.948E-3 3.702E-2
1.750E-1
5.007E-1
 1 19
14 GO:0043235 receptor complex 8.227E-3 3.702E-2
1.750E-1
5.183E-1
 2 339
15 GO:0030125 clathrin vesicle coat 1.045E-2 3.805E-2
1.799E-1
6.581E-1
 1 25
16 GO:0031252 cell leading edge 1.072E-2 3.805E-2
1.799E-1
6.755E-1
 2 389
17 GO:0005925 focal adhesion 1.094E-2 3.805E-2
1.799E-1
6.889E-1
 2 393
18 GO:0005924 cell-substrate adherens junction 1.120E-2 3.805E-2
1.799E-1
7.059E-1
 2 398
19 GO:0030055 cell-substrate junction 1.148E-2 3.805E-2
1.799E-1
7.230E-1
 2 403
20 GO:0030131 clathrin adaptor complex 1.252E-2 3.945E-2
1.865E-1
7.890E-1
 1 30
21 GO:0005912 adherens junction 1.628E-2 4.884E-2
2.309E-1
1.000E0
 2 484
Show 16 more annotations

4: Human Phenotype [Display Chart] 4 input genes in category / 552 annotations before applied cutoff / 4707 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 HP:0003006 Neuroblastoma 2.886E-4 4.104E-2
2.829E-1
1.593E-1
 3 199
2 HP:0030067 Peripheral primitive neuroectodermal neoplasm 2.886E-4 4.104E-2
2.829E-1
1.593E-1
 3 199
3 HP:0030065 Primitive neuroectodermal tumor 2.973E-4 4.104E-2
2.829E-1
1.641E-1
 3 201
4 HP:0004376 Neuroblastic tumors 3.153E-4 4.104E-2
2.829E-1
1.741E-1
 3 205
5 HP:0100843 Glioblastoma 4.835E-4 4.104E-2
2.829E-1
2.669E-1
 2 43
6 HP:0100836 Malignant neoplasm of the central nervous system 6.395E-4 4.104E-2
2.829E-1
3.530E-1
 3 260
7 HP:0000137 Abnormality of the ovary 8.396E-4 4.104E-2
2.829E-1
4.635E-1
 3 285
8 HP:0100501 Recurrent bronchiolitis 8.498E-4 4.104E-2
2.829E-1
4.691E-1
 1 1
9 HP:0009792 Teratoma 9.120E-4 4.104E-2
2.829E-1
5.034E-1
 2 59
10 HP:0002835 Aspiration 9.870E-4 4.104E-2
2.829E-1
5.448E-1
 3 301
11 HP:0100006 Neoplasm of the central nervous system 1.098E-3 4.104E-2
2.829E-1
6.059E-1
 3 312
12 HP:0002185 Neurofibrillary tangles 1.107E-3 4.104E-2
2.829E-1
6.109E-1
 2 65
13 HP:0009824 Upper limb undergrowth 1.129E-3 4.104E-2
2.829E-1
6.233E-1
 3 315
14 HP:0002885 Medulloblastoma 1.320E-3 4.104E-2
2.829E-1
7.287E-1
 2 71
15 HP:0100315 Lewy bodies 1.472E-3 4.104E-2
2.829E-1
8.128E-1
 2 75
16 HP:0100256 Senile plaques 1.674E-3 4.104E-2
2.829E-1
9.242E-1
 2 80
17 HP:0100570 Carcinoid tumor 1.716E-3 4.104E-2
2.829E-1
9.473E-1
 2 81
18 HP:0030063 Neuroepithelial neoplasm 1.730E-3 4.104E-2
2.829E-1
9.550E-1
 3 364
19 HP:0030060 Nervous tissue neoplasm 1.772E-3 4.104E-2
2.829E-1
9.784E-1
 3 367
20 HP:0030061 Neuroectodermal neoplasm 1.772E-3 4.104E-2
2.829E-1
9.784E-1
 3 367
21 HP:0100707 Abnormality of the astrocytes 1.801E-3 4.104E-2
2.829E-1
9.944E-1
 2 83
22 HP:0009592 Astrocytoma 1.801E-3 4.104E-2
2.829E-1
9.944E-1
 2 83
23 HP:0100705 Abnormality of the glial cells 1.815E-3 4.104E-2
2.829E-1
1.000E0
 3 370
24 HP:0004375 Neoplasm of the nervous system 1.889E-3 4.104E-2
2.829E-1
1.000E0
 3 375
25 HP:0010788 Testicular neoplasm 1.933E-3 4.104E-2
2.829E-1
1.000E0
 2 86
26 HP:0100848 Neoplasm of the male external genitalia 1.933E-3 4.104E-2
2.829E-1
1.000E0
 2 86
27 HP:0002669 Osteosarcoma 2.210E-3 4.298E-2
2.962E-1
1.000E0
 2 92
28 HP:0100728 Germ cell neoplasia 2.210E-3 4.298E-2
2.962E-1
1.000E0
 2 92
29 HP:0002862 Bladder carcinoma 2.258E-3 4.298E-2
2.962E-1
1.000E0
 2 93
30 HP:0100314 Cerebral inclusion bodies 2.356E-3 4.334E-2
2.987E-1
1.000E0
 2 95
31 HP:0200016 Acrokeratosis 2.548E-3 4.489E-2
3.094E-1
1.000E0
 1 3
32 HP:0100242 Sarcoma 2.636E-3 4.489E-2
3.094E-1
1.000E0
 3 420
33 HP:0001824 Weight loss 2.729E-3 4.489E-2
3.094E-1
1.000E0
 3 425
34 HP:0100031 Neoplasm of the thyroid gland 2.765E-3 4.489E-2
3.094E-1
1.000E0
 2 103
35 HP:0009733 Glioma 2.927E-3 4.616E-2
3.181E-1
1.000E0
 2 106
36 HP:0031093 Abnormal breast morphology 3.082E-3 4.720E-2
3.253E-1
1.000E0
 3 443
37 HP:0000769 Abnormality of the breast 3.164E-3 4.720E-2
3.253E-1
1.000E0
 3 447
38 HP:0000771 Gynecomastia 3.438E-3 4.867E-2
3.354E-1
1.000E0
 2 115
39 HP:0000770 Male breast abnormality 3.438E-3 4.867E-2
3.354E-1
1.000E0
 2 115
40 HP:0009725 Bladder neoplasm 3.618E-3 4.903E-2
3.379E-1
1.000E0
 2 118
41 HP:0002143 Abnormality of the spinal cord 3.642E-3 4.903E-2
3.379E-1
1.000E0
 3 469
Show 36 more annotations

5: Mouse Phenotype [Display Chart] 6 input genes in category / 555 annotations before applied cutoff / 10355 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 MP:0001176 abnormal lung development 7.810E-5 1.986E-2
1.370E-1
 4.335E-2 3 166
2 MP:0000422 delayed hair appearance 9.038E-5 1.986E-2
1.370E-1
5.016E-2
 2 26
3 MP:0003115 abnormal respiratory system development 1.186E-4 1.986E-2
1.370E-1
6.583E-2
 3 191
4 MP:0010392 prolonged QRS complex duration 2.384E-4 1.986E-2
1.370E-1
1.323E-1
 2 42
5 MP:0006027 impaired lung alveolus development 2.384E-4 1.986E-2
1.370E-1
1.323E-1
 2 42
6 MP:0010636 bundle branch block 2.618E-4 1.986E-2
1.370E-1
1.453E-1
 2 44
7 MP:0010560 intraventricular block 2.618E-4 1.986E-2
1.370E-1
1.453E-1
 2 44
8 MP:0010995 abnormal lung alveolus development 2.863E-4 1.986E-2
1.370E-1
1.589E-1
 2 46
9 MP:0001179 thick pulmonary interalveolar septum 3.386E-4 2.033E-2
1.402E-1
1.879E-1
 2 50
10 MP:0003898 abnormal QRS complex 3.663E-4 2.033E-2
1.402E-1
2.033E-1
 2 52
11 MP:0003233 prolonged QT interval 4.403E-4 2.221E-2
1.532E-1
2.444E-1
 2 57
12 MP:0010900 abnormal pulmonary interalveolar septum morphology 4.879E-4 2.251E-2
1.553E-1
2.708E-1
 2 60
13 MP:0010232 delayed skin pigmentation appearance 5.794E-4 2.251E-2
1.553E-1
3.216E-1
 1 1
14 MP:0011090 perinatal lethality, incomplete penetrance 6.079E-4 2.251E-2
1.553E-1
3.374E-1
 3 332
15 MP:0003899 abnormal QT interval 6.084E-4 2.251E-2
1.553E-1
3.376E-1
 2 67
16 MP:0001951 abnormal breathing pattern 7.645E-4 2.652E-2
1.829E-1
4.243E-1
 3 359
17 MP:0001882 abnormal lactation 1.048E-3 3.062E-2
2.112E-1
5.814E-1
 2 88
18 MP:0010559 heart block 1.144E-3 3.062E-2
2.112E-1
6.351E-1
 2 92
19 MP:0000446 long snout 1.159E-3 3.062E-2
2.112E-1
6.430E-1
 1 2
20 MP:0008899 plush coat 1.159E-3 3.062E-2
2.112E-1
6.430E-1
 1 2
21 MP:0001013 enlarged superior cervical ganglion 1.159E-3 3.062E-2
2.112E-1
6.430E-1
 1 2
22 MP:0002327 abnormal respiratory function 1.260E-3 3.179E-2
2.192E-1
6.993E-1
 3 426
23 MP:0004391 abnormal respiratory conducting tube morphology 1.350E-3 3.259E-2
2.248E-1
7.495E-1
 2 100
24 MP:0013555 abnormal apocrine gland physiology 1.544E-3 3.351E-2
2.311E-1
8.571E-1
 2 107
25 MP:0001881 abnormal mammary gland physiology 1.544E-3 3.351E-2
2.311E-1
8.571E-1
 2 107
26 MP:0002626 increased heart rate 1.602E-3 3.351E-2
2.311E-1
8.892E-1
 2 109
27 MP:0013542 abnormal submandibular gland branching morphogenesis 1.737E-3 3.351E-2
2.311E-1
9.643E-1
 1 3
28 MP:0000968 abnormal sensory neuron innervation pattern 1.751E-3 3.351E-2
2.311E-1
9.717E-1
 2 114
29 MP:0002095 abnormal skin pigmentation 1.751E-3 3.351E-2
2.311E-1
9.717E-1
 2 114
30 MP:0011239 abnormal skin coloration 2.002E-3 3.704E-2
2.555E-1
1.000E0
 2 122
31 MP:0008940 delayed balanopreputial separation 2.316E-3 3.781E-2
2.608E-1
1.000E0
 1 4
32 MP:0009801 abnormal hair cortex keratinization 2.316E-3 3.781E-2
2.608E-1
1.000E0
 1 4
33 MP:0008862 asymmetric snout 2.316E-3 3.781E-2
2.608E-1
1.000E0
 1 4
34 MP:0006026 dilated terminal bronchiole tubes 2.316E-3 3.781E-2
2.608E-1
1.000E0
 1 4
35 MP:0000399 increased curvature of guard hairs 2.894E-3 4.227E-2
2.916E-1
1.000E0
 1 5
36 MP:0001316 corneal scarring 2.894E-3 4.227E-2
2.916E-1
1.000E0
 1 5
37 MP:0001221 epidermal atrophy 2.894E-3 4.227E-2
2.916E-1
1.000E0
 1 5
38 MP:0000583 long toenails 2.894E-3 4.227E-2
2.916E-1
1.000E0
 1 5
39 MP:0006265 increased pulse pressure 3.472E-3 4.683E-2
3.230E-1
1.000E0
 1 6
40 MP:0013541 abnormal submandibular gland development 3.472E-3 4.683E-2
3.230E-1
1.000E0
 1 6
41 MP:0030191 narrow snout 3.472E-3 4.683E-2
3.230E-1
1.000E0
 1 6
42 MP:0001469 abnormal contextual conditioning behavior 3.673E-3 4.683E-2
3.230E-1
1.000E0
 2 166
43 MP:0003811 abnormal hair cortex morphology 4.050E-3 4.683E-2
3.230E-1
1.000E0
 1 7
44 MP:0003882 abnormal pulse pressure 4.050E-3 4.683E-2
3.230E-1
1.000E0
 1 7
45 MP:0030584 skin atrophy 4.050E-3 4.683E-2
3.230E-1
1.000E0
 1 7
46 MP:0014107 premature chondrocyte differentiation 4.050E-3 4.683E-2
3.230E-1
1.000E0
 1 7
47 MP:0006257 abnormal fungiform papillae morphology 4.050E-3 4.683E-2
3.230E-1
1.000E0
 1 7
48 MP:0008975 delayed male fertility 4.050E-3 4.683E-2
3.230E-1
1.000E0
 1 7
49 MP:0001280 loss of vibrissae 4.628E-3 4.769E-2
3.289E-1
1.000E0
 1 8
50 MP:0000763 abnormal filiform papillae morphology 4.628E-3 4.769E-2
3.289E-1
1.000E0
 1 8
Show 45 more annotations

6: Domain [Display Chart] 8 input genes in category / 66 annotations before applied cutoff / 18735 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 PS00109 PROTEIN KINASE TYR PROSITE 4.652E-8 1.535E-6 7.329E-6 3.070E-6 4 97
2 IPR008266 Tyr kinase AS InterPro 4.652E-8 1.535E-6 7.329E-6 3.070E-6 4 97
3 PF07714 Pkinase Tyr Pfam 1.470E-7 3.181E-6 1.519E-5 9.702E-6 4 129
4 IPR001245 Ser-Thr/Tyr kinase cat dom InterPro 1.928E-7 3.181E-6 1.519E-5 1.273E-5 4 138
5 IPR016245 Tyr kinase EGF/ERB/XmrK rcpt InterPro 9.569E-7 1.263E-5 6.031E-5 6.316E-5 2 4
6 PF14843 GF recep IV Pfam 2.391E-6 1.841E-5 8.789E-5 1.578E-4 2 6
7 IPR032778 GF recep IV InterPro 2.391E-6 1.841E-5 8.789E-5 1.578E-4 2 6
8 PF00757 Furin-like Pfam 3.347E-6 1.841E-5 8.789E-5 2.209E-4 2 7
9 PF01030 Recep L domain Pfam 3.347E-6 1.841E-5 8.789E-5 2.209E-4 2 7
10 3.80.20.20 - Gene3D 3.347E-6 1.841E-5 8.789E-5 2.209E-4 2 7
11 IPR000494 Rcpt L-dom InterPro 3.347E-6 1.841E-5 8.789E-5 2.209E-4 2 7
12 IPR006211 Furin-like Cys-rich dom InterPro 3.347E-6 1.841E-5 8.789E-5 2.209E-4 2 7
13 SM00219 TyrKc SMART 5.513E-6 2.599E-5 1.241E-4 3.639E-4 3 88
14 IPR020635 Tyr kinase cat dom InterPro 5.513E-6 2.599E-5 1.241E-4 3.639E-4 3 88
15 IPR017441 Protein kinase ATP BS InterPro 1.082E-5 4.761E-5 2.273E-4 7.142E-4 4 379
16 PS00107 PROTEIN KINASE ATP PROSITE 2.302E-5 8.920E-5 4.259E-4 1.519E-3 4 459
17 SM00261 FU SMART 2.433E-5 8.920E-5 4.259E-4 1.606E-3 2 18
18 IPR006212 Furin repeat InterPro 2.433E-5 8.920E-5 4.259E-4 1.606E-3 2 18
19 IPR000719 Prot kinase dom InterPro 2.953E-5 1.006E-4 4.803E-4 1.949E-3 4 489
20 PS50011 PROTEIN KINASE DOM PROSITE 3.049E-5 1.006E-4 4.803E-4 2.012E-3 4 493
21 IPR030790 SPRY4 InterPro 4.270E-4 1.281E-3 6.116E-3 2.818E-2 1 1
22 IPR026830 ALK InterPro 4.270E-4 1.281E-3 6.116E-3 2.818E-2 1 1
23 IPR016555 PLipase D1/D2 InterPro 8.539E-4 2.348E-3 1.121E-2
5.635E-2
 1 2
24 IPR015679 PLipase D fam InterPro 8.539E-4 2.348E-3 1.121E-2
5.635E-2
 1 2
25 IPR025202 PLD-like dom InterPro 1.281E-3 3.251E-3 1.552E-2
8.452E-2
 1 3
26 PF13091 PLDc 2 Pfam 1.281E-3 3.251E-3 1.552E-2
8.452E-2
 1 3
27 PF00614 PLDc Pfam 1.707E-3 4.173E-3 1.992E-2
1.127E-1
 1 4
28 IPR009030 Growth fac rcpt InterPro 1.867E-3 4.400E-3 2.101E-2
1.232E-1
 2 156
29 SM00155 PLDc SMART 2.560E-3 5.796E-3 2.767E-2
1.689E-1
 1 6
30 PS51227 SPR PROSITE 2.986E-3 5.796E-3 2.767E-2
1.971E-1
 1 7
31 IPR007875 Sprouty InterPro 2.986E-3 5.796E-3 2.767E-2
1.971E-1
 1 7
32 IPR001736 PLipase D/transphosphatidylase InterPro 2.986E-3 5.796E-3 2.767E-2
1.971E-1
 1 7
33 PF05210 Sprouty Pfam 2.986E-3 5.796E-3 2.767E-2
1.971E-1
 1 7
34 PS50035 PLD PROSITE 2.986E-3 5.796E-3 2.767E-2
1.971E-1
 1 7
35 IPR002011 Tyr kinase rcpt 2 CS InterPro 4.688E-3 8.841E-3 4.221E-2
3.094E-1
 1 11
36 PS00239 RECEPTOR TYR KIN II PROSITE 5.114E-3 9.375E-3 4.476E-2
3.375E-1
 1 12
37 PS00740 MAM 1 PROSITE 6.813E-3 1.215E-2
5.802E-2
4.497E-1
 1 16
38 PF00629 MAM Pfam 7.662E-3 1.264E-2
6.036E-2
5.057E-1
 1 18
39 PS50060 MAM 2 PROSITE 7.662E-3 1.264E-2
6.036E-2
5.057E-1
 1 18
40 IPR000998 MAM dom InterPro 7.662E-3 1.264E-2
6.036E-2
5.057E-1
 1 18
41 IPR032675 L dom-like InterPro 7.980E-3 1.285E-2
6.133E-2
5.267E-1
 2 328
42 SM00312 PX SMART 1.864E-2 2.684E-2
1.281E-1
1.000E0
 1 44
43 IPR002957 Keratin I InterPro 1.864E-2 2.684E-2
1.281E-1
1.000E0
 1 44
44 IPR016201 PSI InterPro 1.864E-2 2.684E-2
1.281E-1
1.000E0
 1 44
45 4.10.400.10 - Gene3D 1.948E-2 2.684E-2
1.281E-1
1.000E0
 1 46
46 SM00423 PSI SMART 1.948E-2 2.684E-2
1.281E-1
1.000E0
 1 46
47 PS01209 LDLRA 1 PROSITE 2.032E-2 2.684E-2
1.281E-1
1.000E0
 1 48
48 PF00787 PX Pfam 2.074E-2 2.684E-2
1.281E-1
1.000E0
 1 49
49 IPR002172 LDrepeatLR classA rpt InterPro 2.074E-2 2.684E-2
1.281E-1
1.000E0
 1 49
50 SM00192 LDLa SMART 2.074E-2 2.684E-2
1.281E-1
1.000E0
 1 49
Show 45 more annotations

7: Pathway [Display Chart] 6 input genes in category / 187 annotations before applied cutoff / 12450 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 P00018 EGF receptor signaling pathway PantherDB 1.353E-5 8.661E-4 5.033E-3 2.530E-3 3 111
2 1383024 ERBB2 Activates PTK6 Signaling BioSystems: REACTOME 1.506E-5 8.661E-4 5.033E-3 2.817E-3 2 13
3 1383023 ERBB2 Regulates Cell Motility BioSystems: REACTOME 2.027E-5 8.661E-4 5.033E-3 3.790E-3 2 15
4 1269492 PI3K events in ERBB2 signaling BioSystems: REACTOME 2.316E-5 8.661E-4 5.033E-3 4.330E-3 2 16
5 1269491 GRB2 events in ERBB2 signaling BioSystems: REACTOME 2.316E-5 8.661E-4 5.033E-3 4.330E-3 2 16
6 M1389 Sprouty regulation of tyrosine kinase signals MSigDB C2 BIOCARTA (v6.0) 2.951E-5 9.198E-4 5.345E-3 5.519E-3 2 18
7 1269490 SHC1 events in ERBB2 signaling BioSystems: REACTOME 4.452E-5 1.041E-3 6.047E-3 8.325E-3 2 22
8 M18719 Role of ERBB2 in Signal Transduction and Oncology MSigDB C2 BIOCARTA (v6.0) 4.452E-5 1.041E-3 6.047E-3 8.325E-3 2 22
9 1457793 Downregulation of ERBB2 signaling BioSystems: REACTOME 8.370E-5 1.739E-3 1.011E-2 1.565E-2 2 30
10 102279 Endocytosis BioSystems: KEGG 1.719E-4 2.945E-3 1.712E-2 3.214E-2 3 260
11 1269496 Signaling by ERBB4 BioSystems: REACTOME 1.733E-4 2.945E-3 1.712E-2 3.240E-2 2 43
12 1269489 Signaling by ERBB2 BioSystems: REACTOME 2.442E-4 3.806E-3 2.211E-2 4.567E-2 2 51
13 83119 Non-small cell lung cancer BioSystems: KEGG 3.161E-4 4.548E-3 2.643E-2
5.912E-2
 2 58
14 137928 LPA receptor mediated events BioSystems: Pathway Interaction Database 3.972E-4 4.952E-3 2.877E-2
7.428E-2
 2 65
15 1268880 Constitutive Signaling by Aberrant PI3K in Cancer BioSystems: REACTOME 3.972E-4 4.952E-3 2.877E-2
7.428E-2
 2 65
16 1383025 Signaling by PTK6 BioSystems: REACTOME 4.347E-4 5.081E-3 2.953E-2
8.130E-2
 2 68
17 83049 ErbB signaling pathway BioSystems: KEGG 6.948E-4 7.299E-3 4.242E-2
1.299E-1
 2 86
18 1383020 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling BioSystems: REACTOME 7.110E-4 7.299E-3 4.242E-2
1.330E-1
 2 87
19 1268879 PI3K/AKT Signaling in Cancer BioSystems: REACTOME 7.607E-4 7.299E-3 4.242E-2
1.423E-1
 2 90
20 83091 GnRH signaling pathway BioSystems: KEGG 7.947E-4 7.299E-3 4.242E-2
1.486E-1
 2 92
21 1269191 Negative regulation of the PI3K/AKT network BioSystems: REACTOME 8.295E-4 7.299E-3 4.242E-2
1.551E-1
 2 94
22 1059539 Choline metabolism in cancer BioSystems: KEGG 9.196E-4 7.299E-3 4.242E-2
1.720E-1
 2 99
23 1268862 Inhibition of Signaling by Overexpressed EGFR BioSystems: REACTOME 9.637E-4 7.299E-3 4.242E-2
1.802E-1
 1 2
24 1268861 Signaling by Overexpressed Wild-Type EGFR in Cancer BioSystems: REACTOME 9.637E-4 7.299E-3 4.242E-2
1.802E-1
 1 2
25 138057 ErbB1 downstream signaling BioSystems: Pathway Interaction Database 9.759E-4 7.299E-3 4.242E-2
1.825E-1
 2 102
26 1269188 PIP3 activates AKT signaling BioSystems: REACTOME 1.461E-3 1.023E-2
5.943E-2
2.732E-1
 2 125
27 1269384 GAB1 signalosome BioSystems: REACTOME 1.531E-3 1.023E-2
5.943E-2
2.863E-1
 2 128
28 1269473 PI3K/AKT activation BioSystems: REACTOME 1.531E-3 1.023E-2
5.943E-2
2.863E-1
 2 128
29 1269302 Role of LAT2/NTAL/LAB on calcium mobilization BioSystems: REACTOME 1.752E-3 1.130E-2
6.564E-2
3.276E-1
 2 137
30 1269493 PLCG1 events in ERBB2 signaling BioSystems: REACTOME 1.927E-3 1.161E-2
6.746E-2
3.603E-1
 1 4
31 PW:0000170 epidermal growth factor/neuregulin signaling Pathway Ontology 1.927E-3 1.161E-2
6.746E-2
3.603E-1
 1 4
32 1311074 Phospholipase D signaling pathway BioSystems: KEGG 1.986E-3 1.161E-2
6.746E-2
3.715E-1
 2 146
33 P00012 Cadherin signaling pathway PantherDB 2.351E-3 1.324E-2
7.695E-2
4.396E-1
 2 159
34 PW:0000155 phospholipid metabolic Pathway Ontology 2.408E-3 1.324E-2
7.695E-2
4.502E-1
 1 5
35 1383032 PTK6 promotes HIF1A stabilization BioSystems: REACTOME 2.889E-3 1.543E-2
8.969E-2
5.402E-1
 1 6
36 83050 Calcium signaling pathway BioSystems: KEGG 3.067E-3 1.593E-2
9.258E-2
5.736E-1
 2 182
37 1269185 Downstream signaling events of B Cell Receptor (BCR) BioSystems: REACTOME 3.655E-3 1.756E-2
1.020E-1
6.835E-1
 2 199
38 782000 Proteoglycans in cancer BioSystems: KEGG 3.801E-3 1.756E-2
1.020E-1
7.107E-1
 2 203
39 138037 EGFR-dependent Endothelin signaling events BioSystems: Pathway Interaction Database 3.850E-3 1.756E-2
1.020E-1
7.200E-1
 1 8
40 1269500 Downregulation of ERBB4 signaling BioSystems: REACTOME 3.850E-3 1.756E-2
1.020E-1
7.200E-1
 1 8
41 1270068 Synthesis of PG BioSystems: REACTOME 3.850E-3 1.756E-2
1.020E-1
7.200E-1
 1 8
42 1269593 EGFR Transactivation by Gastrin BioSystems: REACTOME 4.330E-3 1.906E-2
1.107E-1
8.098E-1
 1 9
43 868085 Ras signaling pathway BioSystems: KEGG 4.731E-3 1.906E-2
1.107E-1
8.846E-1
 2 227
44 1269498 PI3K events in ERBB4 signaling BioSystems: REACTOME 4.811E-3 1.906E-2
1.107E-1
8.996E-1
 1 10
45 1269183 Signaling by the B Cell Receptor (BCR) BioSystems: REACTOME 5.104E-3 1.906E-2
1.107E-1
9.544E-1
 2 236
46 M18837 Map Kinase Inactivation of SMRT Corepressor MSigDB C2 BIOCARTA (v6.0) 5.291E-3 1.906E-2
1.107E-1
9.893E-1
 1 11
47 1269382 GRB2 events in EGFR signaling BioSystems: REACTOME 5.623E-3 1.906E-2
1.107E-1
1.000E0
 2 248
48 1269440 SOS-mediated signalling BioSystems: REACTOME 5.623E-3 1.906E-2
1.107E-1
1.000E0
 2 248
49 1269383 SHC1 events in EGFR signaling BioSystems: REACTOME 5.623E-3 1.906E-2
1.107E-1
1.000E0
 2 248
50 1269285 RAF/MAP kinase cascade BioSystems: REACTOME 5.623E-3 1.906E-2
1.107E-1
1.000E0
 2 248
Show 45 more annotations

8: Pubmed [Display Chart] 8 input genes in category / 7401 annotations before applied cutoff / 38193 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 25575117 Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
2 23154552 Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
3 25434695 A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
4 26537995 Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
5 25740878 Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
6 26555338 Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
7 27225694 EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
8 26422230 Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
9 29199696 Dual mutations and complex mutations in metastatic nonsmall cell lung cancer: A single-institution experience from South India. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
10 24443522 Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
11 25682925 Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
12 24338375 Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
13 28987389 Environmental tobacco smoke exposure and EGFR and ALK alterations in never smokers' lung cancer. Results from the LCRINS study. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
14 9837959 PLD2 complexes with the EGF receptor and undergoes tyrosine phosphorylation at a single site upon agonist stimulation. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
15 26505450 Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
16 28557060 Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
17 11919185 A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
18 16554459 Neuregulin 1-erbB signaling is necessary for normal myelination and sensory function. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
19 23683537 Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
20 22282022 Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
21 25577516 Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
22 22569898 Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
23 28433570 Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
24 27776643 Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
25 29582563 Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
26 15591145 erbB-1 and erbB-4 receptors act in concert to facilitate female sexual development and mature reproductive function. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
27 23927961 Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
28 30201068 [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer]. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
29 28561721 Managing Resistance to EFGR- and ALK-Targeted Therapies. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
30 24885886 Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity. Pubmed 3.839E-8 9.471E-6 8.985E-5 2.841E-4 2 2
31 30037374 [Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant â?©Organ Metastasis in Non-small Cell Lung Cancer]. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
32 26789109 Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
33 25468910 Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
34 24389444 Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
35 28743163 ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
36 28720066 High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
37 24935562 Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
38 12446727 ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
39 28359267 Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
40 25757141 ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
41 28232522 ErbB1 and ErbB4 generate opposing signals regulating mesenchymal cell proliferation during valvulogenesis. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
42 24862237 Absence of EGFR, ERBB2 and ERBB4 mutation homologous to the oncogenic ERBB3 Val-104 mutation in colorectal cancers. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
43 25854400 Effects of EGFR, CK19, CK20 and Survinin gene expression on radiotherapy results in patients with locally advanced head and neck cancer. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
44 14691459 A ligand-inducible anaplastic lymphoma kinase chimera is endocytosis impaired. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
45 21420271 [Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
46 29199690 Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
47 26992209 Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
48 23932486 Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
49 23238254 Serum deprivation confers the MDA-MB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
50 18424286 Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. Pubmed 1.152E-7 1.168E-5 1.108E-4 8.523E-4 2 3
Show 45 more annotations

9: Interaction [Display Chart] 8 input genes in category / 1384 annotations before applied cutoff / 17703 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 int:DUSP19 DUSP19 interactions 2.285E-8 3.163E-5 2.470E-4 3.163E-5 4 77
2 int:PPM1A PPM1A interactions 8.999E-8 6.227E-5 4.864E-4 1.245E-4 4 108
3 int:PPM1F PPM1F interactions 2.445E-7 1.128E-4 8.810E-4 3.384E-4 3 30
4 int:PTPRR PTPRR interactions 7.412E-7 2.565E-4 2.003E-3 1.026E-3 3 43
5 int:ILKAP ILKAP interactions 2.153E-6 5.475E-4 4.276E-3 2.980E-3 3 61
6 int:EREG EREG interactions 2.678E-6 5.475E-4 4.276E-3 3.706E-3 2 6
7 int:DUSP14 DUSP14 interactions 2.994E-6 5.475E-4 4.276E-3 4.144E-3 3 68
8 int:STYX STYX interactions 3.269E-6 5.475E-4 4.276E-3 4.524E-3 3 70
9 int:PTPN12 PTPN12 interactions 3.560E-6 5.475E-4 4.276E-3 4.927E-3 3 72
10 int:PTPRT PTPRT interactions 6.423E-6 8.081E-4 6.312E-3 8.889E-3 2 9
11 int:PTPN20 PTPN20 interactions 6.423E-6 8.081E-4 6.312E-3 8.889E-3 2 9
12 int:BTC BTC interactions 9.808E-6 1.131E-3 8.835E-3 1.357E-2 2 11
13 int:CDC25C CDC25C interactions 1.385E-5 1.374E-3 1.074E-2 1.918E-2 3 113
14 int:HBEGF HBEGF interactions 1.390E-5 1.374E-3 1.074E-2 1.924E-2 2 13
15 int:SOCS5 SOCS5 interactions 1.622E-5 1.496E-3 1.169E-2 2.244E-2 2 14
16 int:CAV2 CAV2 interactions 1.871E-5 1.523E-3 1.190E-2 2.589E-2 2 15
17 int:ANKS1B ANKS1B interactions 1.871E-5 1.523E-3 1.190E-2 2.589E-2 2 15
18 int:PIK3R2 PIK3R2 interactions 2.259E-5 1.737E-3 1.356E-2 3.126E-2 3 133
19 int:TGFA TGFA interactions 2.724E-5 1.984E-3 1.550E-2 3.770E-2 2 18
20 int:DUSP18 DUSP18 interactions 3.737E-5 2.463E-3 1.923E-2
5.171E-2
 2 21
21 int:SHC3 SHC3 interactions 3.737E-5 2.463E-3 1.923E-2
5.171E-2
 2 21
22 int:CCN2 CCN2 interactions 4.500E-5 2.732E-3 2.134E-2
6.228E-2
 2 23
23 int:PLCG1 PLCG1 interactions 4.540E-5 2.732E-3 2.134E-2
6.283E-2
 3 168
24 int:UBASH3A UBASH3A interactions 4.908E-5 2.830E-3 2.210E-2
6.792E-2
 2 24
25 int:PTPN6 PTPN6 interactions 5.215E-5 2.887E-3 2.255E-2
7.218E-2
 3 176
26 int:LRIG1 LRIG1 interactions 6.715E-5 3.575E-3 2.792E-2
9.294E-2
 2 28
27 int:ANKS1A ANKS1A interactions 8.255E-5 4.232E-3 3.305E-2
1.143E-1
 2 31
28 int:PTPRH PTPRH interactions 8.803E-5 4.351E-3 3.399E-2
1.218E-1
 2 32
29 int:MTMR6 MTMR6 interactions 1.055E-4 5.037E-3 3.934E-2
1.461E-1
 2 35
30 int:PTPN7 PTPN7 interactions 1.246E-4 5.749E-3 4.490E-2
1.725E-1
 2 38
31 int:PTPDC1 PTPDC1 interactions 1.313E-4 5.862E-3 4.579E-2
1.817E-1
 2 39
32 int:ABL2 ABL2 interactions 1.675E-4 7.242E-3
5.656E-2
2.318E-1
 2 44
33 int:CBL CBL interactions 1.877E-4 7.872E-3
6.148E-2
2.598E-1
 3 271
34 int:SHC1 SHC1 interactions 2.024E-4 8.222E-3
6.422E-2
2.801E-1
 3 278
35 int:PIK3CB PIK3CB interactions 2.079E-4 8.222E-3
6.422E-2
2.878E-1
 2 49
36 int:MUC1 MUC1 interactions 2.527E-4 9.716E-3
7.588E-2
3.498E-1
 2 54
37 int:PLD2 PLD2 interactions 2.622E-4 9.808E-3
7.660E-2
3.629E-1
 2 55
38 int:EXOC8 EXOC8 interactions 3.018E-4 1.099E-2
8.586E-2
4.177E-1
 2 59
39 int:DUSP6 DUSP6 interactions 3.122E-4 1.108E-2
8.652E-2
4.320E-1
 2 60
40 int:PPP3CB PPP3CB interactions 3.442E-4 1.191E-2
9.302E-2
4.764E-1
 2 63
41 int:CDK13 CDK13 interactions 3.552E-4 1.199E-2
9.366E-2
4.917E-1
 2 64
42 int:NRG1 NRG1 interactions 4.372E-4 1.441E-2
1.125E-1
6.051E-1
 2 71
43 int:SOS1 SOS1 interactions 4.621E-4 1.487E-2
1.162E-1
6.396E-1
 2 73
44 int:CSK CSK interactions 5.548E-4 1.525E-2
1.191E-1
7.679E-1
 2 80
45 int:ACTB ACTB interactions 5.722E-4 1.525E-2
1.191E-1
7.919E-1
 3 396
46 int:SOCS1 SOCS1 interactions 5.828E-4 1.525E-2
1.191E-1
8.066E-1
 2 82
47 int:SRC SRC interactions 6.110E-4 1.525E-2
1.191E-1
8.456E-1
 3 405
48 int:STAT5B STAT5B interactions 6.115E-4 1.525E-2
1.191E-1
8.463E-1
 2 84
49 int:RASA1 RASA1 interactions 6.261E-4 1.525E-2
1.191E-1
8.665E-1
 2 85
50 int:USP8 USP8 interactions 6.261E-4 1.525E-2
1.191E-1
8.665E-1
 2 85
Show 45 more annotations

10: Cytoband [Display Chart] 8 input genes in category / 8 annotations before applied cutoff / 34661 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 2q33.3-q34 2q33.3-q34 4.616E-4 2.769E-3 7.526E-3 3.693E-3 1 2
2 7p12 7p12 6.923E-4 2.769E-3 7.526E-3 5.538E-3 1 3
3 2p23 2p23 3.917E-3 1.045E-2 2.839E-2 3.134E-2 1 17
4 5q31.3 5q31.3 8.280E-3 1.581E-2 4.298E-2
6.624E-2
 1 36
5 7q21.3 7q21.3 9.883E-3 1.581E-2 4.298E-2
7.906E-2
 1 43
6 17q21.2 17q21.2 1.718E-2 2.291E-2
6.226E-2
1.375E-1
 1 75
7 17p13.1 17p13.1 2.782E-2 3.119E-2
8.477E-2
2.225E-1
 1 122
8 21q22.3 21q22.3 3.119E-2 3.119E-2
8.477E-2
2.495E-1
 1 137
Show 3 more annotations

11: Transcription Factor Binding Site [Display Chart] 5 input genes in category / 80 annotations before applied cutoff / 9770 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 V$COMP1 01 V$COMP1 01 9.568E-4 4.698E-2
2.333E-1
7.655E-2
 2 97
2 YYCATTCAWW UNKNOWN YYCATTCAWW UNKNOWN 2.517E-3 4.698E-2
2.333E-1
2.014E-1
 2 158
3 V$GATA Q6 V$GATA Q6 2.808E-3 4.698E-2
2.333E-1
2.246E-1
 2 167
4 V$CEBPB 01 V$CEBPB 01 4.324E-3 4.698E-2
2.333E-1
3.459E-1
 2 208
5 V$AP3 Q6 V$AP3 Q6 4.324E-3 4.698E-2
2.333E-1
3.459E-1
 2 208
6 V$HLF 01 V$HLF 01 4.324E-3 4.698E-2
2.333E-1
3.459E-1
 2 208
7 V$ZIC1 01 V$ZIC1 01 4.656E-3 4.698E-2
2.333E-1
3.725E-1
 2 216
8 V$CEBP Q2 01 V$CEBP Q2 01 4.698E-3 4.698E-2
2.333E-1
3.759E-1
 2 217
Show 3 more annotations

12: Gene Family [Display Chart] 6 input genes in category / 6 annotations before applied cutoff / 18194 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 1096 Erb-b2 receptor tyrosine kinases genenames.org 5.436E-7 3.262E-6 7.992E-6 3.262E-6 2 4
2 321 Receptor Tyrosine Kinases|Protein phosphatase 1 regulatory subunits genenames.org 7.030E-5 2.109E-4 5.167E-4 4.218E-4 2 40
3 608 Keratins, type I genenames.org 9.200E-3 1.840E-2 4.508E-2
5.520E-2
 1 28
4 467 Phospholipases genenames.org 1.377E-2 2.066E-2
5.062E-2
8.264E-2
 1 42

13: Coexpression [Display Chart] 8 input genes in category / 797 annotations before applied cutoff / 23137 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 M18219 Growth factor signaling components up-regulated in hepatocellular carcinoma (HCC). MSigDB C2: CGP Curated Gene Sets (v6.0) 2.408E-5 8.995E-3
6.529E-2
 1.919E-2 2 22
2 M16488 The lung adenocarcinoma TSP (tumor sequencing project) genes that were found significantly mutated by at least one method. MSigDB C2: CGP Curated Gene Sets (v6.0) 3.386E-5 8.995E-3
6.529E-2
 2.699E-2 2 26
3 11965276-Table1 Human Sarcoma Nielsen02 36genes GeneSigDB 3.386E-5 8.995E-3
6.529E-2
 2.699E-2 2 26
4 15606925-Table3 Human Breast Bieche04 47genes GeneSigDB 1.075E-4 2.141E-2
1.554E-1
8.564E-2
 2 46
5 16024625-Table1 Human Colon Craene05 85genes GeneSigDB 2.791E-4 4.119E-2
2.990E-1
2.224E-1
 2 74
6 16849537-Table1 Human StemCell Davicioni06 81genes GeneSigDB 3.101E-4 4.119E-2
2.990E-1
2.471E-1
 2 78
Show 1 more annotation

14: Coexpression Atlas [Display Chart] 8 input genes in category / 637 annotations before applied cutoff / 21829 genes in category

No results to display

15: Computational [Display Chart] 5 input genes in category / 28 annotations before applied cutoff / 10037 genes in category

No results to display

16: MicroRNA [Display Chart] 8 input genes in category / 401 annotations before applied cutoff / 72241 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 hsa-miR-138-5p:TargetScan hsa-miR-138-5p TargetScan 1.653E-5 4.287E-3 2.818E-2 6.627E-3 3 486
2 hsa-miR-6728-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.635E-5 4.287E-3 2.818E-2 1.458E-2 2 83
3 hsa-miR-450b-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.904E-5 4.287E-3 2.818E-2 1.565E-2 2 86
4 hsa-miR-4425:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.277E-5 4.287E-3 2.818E-2 1.715E-2 2 90
5 hsa-miR-411-5p.2:TargetScan hsa-miR-411-5p.2 TargetScan 5.497E-5 4.408E-3 2.897E-2 2.204E-2 2 102
6 hsa-miR-146b-5p:Functional MTI Functional MTI miRTarbase 7.739E-5 5.172E-3 3.400E-2 3.103E-2 2 121
7 hsa-miR-769-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.439E-4 7.836E-3
5.150E-2
5.770E-2
 2 165
8 hsa-miR-491-5p:Functional MTI Functional MTI miRTarbase 1.563E-4 7.836E-3
5.150E-2
6.269E-2
 2 172
9 hsa-miR-337-3p:PITA hsa-miR-337-3p:PITA TOP PITA 1.967E-4 8.639E-3
5.678E-2
7.889E-2
 2 193
10 hsa-miR-146a-5p:Functional MTI Functional MTI miRTarbase 2.154E-4 8.639E-3
5.678E-2
8.639E-2
 2 202
11 hsa-miR-411-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.440E-4 8.894E-3
5.845E-2
9.783E-2
 2 215
12 hsa-miR-145-5p:Functional MTI Functional MTI miRTarbase 2.987E-4 9.603E-3
6.312E-2
1.198E-1
 2 238
13 hsa-miR-1236-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.113E-4 9.603E-3
6.312E-2
1.248E-1
 2 243
14 hsa-miR-132-3p:Functional MTI Functional MTI miRTarbase 3.427E-4 9.815E-3
6.451E-2
1.374E-1
 2 255
15 hsa-miR-365a-3p:TargetScan hsa-miR-365a-3p TargetScan 4.275E-4 1.045E-2
6.866E-2
1.714E-1
 2 285
16 hsa-miR-365b-3p:TargetScan hsa-miR-365b-3p TargetScan 4.275E-4 1.045E-2
6.866E-2
1.714E-1
 2 285
17 hsa-miR-128b:Functional MTI Functional MTI miRTarbase 4.429E-4 1.045E-2
6.866E-2
1.776E-1
 1 4
18 hsa-miR-140-5p:TargetScan hsa-miR-140-5p TargetScan 4.703E-4 1.048E-2
6.885E-2
1.886E-1
 2 299
19 hsa-miR-513b:PITA hsa-miR-513b:PITA TOP PITA 5.482E-4 1.157E-2
7.604E-2
2.198E-1
 2 323
20 hsa-miR-551b-3p:TargetScan hsa-miR-551b-3p TargetScan 6.643E-4 1.238E-2
8.137E-2
2.664E-1
 1 6
21 hsa-miR-551a:TargetScan hsa-miR-551a TargetScan 6.643E-4 1.238E-2
8.137E-2
2.664E-1
 1 6
22 hsa-miR-5089-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 7.255E-4 1.238E-2
8.137E-2
2.909E-1
 2 372
23 hsa-miR-222-3p:TargetScan hsa-miR-222-3p TargetScan 7.410E-4 1.238E-2
8.137E-2
2.971E-1
 2 376
24 hsa-miR-221-3p:TargetScan hsa-miR-221-3p TargetScan 7.410E-4 1.238E-2
8.137E-2
2.971E-1
 2 376
25 hsa-miR-6513-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 8.048E-4 1.282E-2
8.424E-2
3.227E-1
 2 392
26 hsa-miR-7-5p:TargetScan hsa-miR-7-5p TargetScan 8.585E-4 1.282E-2
8.424E-2
3.443E-1
 2 405
27 TGCACTT,MIR-519A:MSigDB TGCACTT,MIR-519A:MSigDB MSigDB 9.269E-4 1.282E-2
8.424E-2
3.717E-1
 2 421
28 TGCACTT,MIR-519B:MSigDB TGCACTT,MIR-519B:MSigDB MSigDB 9.269E-4 1.282E-2
8.424E-2
3.717E-1
 2 421
29 TGCACTT,MIR-519C:MSigDB TGCACTT,MIR-519C:MSigDB MSigDB 9.269E-4 1.282E-2
8.424E-2
3.717E-1
 2 421
30 hsa-miR-302b-3p:Functional MTI Functional MTI miRTarbase 1.104E-3 1.447E-2
9.511E-2
4.429E-1
 2 460
31 hsa-miR-1306:mirSVR lowEffct hsa-miR-1306:mirSVR nonconserved lowEffect-0.1-0.5 MicroRNA.org 1.119E-3 1.447E-2
9.511E-2
4.486E-1
 2 463
32 hsa-miR-551a:PITA hsa-miR-551a:PITA TOP PITA 1.328E-3 1.614E-2
1.061E-1
5.326E-1
 1 12
33 hsa-miR-551b:PITA hsa-miR-551b:PITA TOP PITA 1.328E-3 1.614E-2
1.061E-1
5.326E-1
 1 12
34 hsa-miR-887-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 1.881E-3 2.219E-2
1.458E-1
7.543E-1
 1 17
35 hsa-miR-664b-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.323E-3 2.662E-2
1.749E-1
9.316E-1
 1 21
36 hsa-miR-574-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 2.986E-3 3.326E-2
2.186E-1
1.000E0
 1 27
37 hsa-miR-1181:mirSVR highEffct hsa-miR-1181:mirSVR nonconserved highEffect-0.5 MicroRNA.org 3.207E-3 3.476E-2
2.284E-1
1.000E0
 1 29
38 hsa-miR-7848-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.318E-3 3.501E-2
2.301E-1
1.000E0
 1 30
39 hsa-miR-6881-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.538E-3 3.638E-2
2.391E-1
1.000E0
 1 32
40 hsa-miR-542-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 3.759E-3 3.769E-2
2.477E-1
1.000E0
 1 34
41 hsa-miR-133a-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.752E-3 4.334E-2
2.849E-1
1.000E0
 1 43
42 hsa-miR-875-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 4.862E-3 4.334E-2
2.849E-1
1.000E0
 1 44
43 hsa-miR-27a-5p:Functional MTI Functional MTI miRTarbase 4.973E-3 4.334E-2
2.849E-1
1.000E0
 1 45
44 hsa-miR-219a-5p:Functional MTI Functional MTI miRTarbase 5.083E-3 4.334E-2
2.849E-1
1.000E0
 1 46
45 hsa-miR-3162-3p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.193E-3 4.334E-2
2.849E-1
1.000E0
 1 47
46 hsa-miR-4320:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.414E-3 4.334E-2
2.849E-1
1.000E0
 1 49
47 hsa-miR-4259:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.744E-3 4.334E-2
2.849E-1
1.000E0
 1 52
48 hsa-miR-378j:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.854E-3 4.334E-2
2.849E-1
1.000E0
 1 53
49 hsa-miR-6839-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.854E-3 4.334E-2
2.849E-1
1.000E0
 1 53
50 hsa-miR-1-5p:Functional MTI (Weak) Functional MTI (Weak) miRTarbase 5.965E-3 4.334E-2
2.849E-1
1.000E0
 1 54
Show 45 more annotations

17: Drug [Display Chart] 8 input genes in category / 3163 annotations before applied cutoff / 22841 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 CID014758064 pyrido[3,4-d]pyrimidine Stitch 3.220E-7 6.362E-4 5.494E-3 1.018E-3 2 3
2 CID000004708 PD168393 Stitch 6.438E-7 6.362E-4 5.494E-3 2.036E-3 2 4
3 CID000765653 6-quinolinecarbaldehyde Stitch 1.073E-6 6.362E-4 5.494E-3 3.393E-3 2 5
4 CID000197517 RG 14921 Stitch 1.073E-6 6.362E-4 5.494E-3 3.393E-3 2 5
5 CID000158548 SCH 49210 Stitch 1.609E-6 6.362E-4 5.494E-3 5.089E-3 2 6
6 CID000164259 SnCe6 Stitch 1.609E-6 6.362E-4 5.494E-3 5.089E-3 2 6
7 CID006450172 Cochliobolic acid Stitch 1.609E-6 6.362E-4 5.494E-3 5.089E-3 2 6
8 CID000264327 diethyl ester Stitch 1.609E-6 6.362E-4 5.494E-3 5.089E-3 2 6
9 CID000003248 methyl 2,5-dihydroxycinnamate Stitch 2.038E-6 6.476E-4 5.593E-3 6.446E-3 3 77
10 CID003035734 SSFSB Stitch 2.252E-6 6.476E-4 5.593E-3 7.124E-3 2 7
11 CID000132069 RG 14467 Stitch 2.252E-6 6.476E-4 5.593E-3 7.124E-3 2 7
12 CID000083651 I50 - 9 Stitch 3.002E-6 7.914E-4 6.835E-3 9.497E-3 2 8
13 CID003056529 H 661 Stitch 4.824E-6 1.017E-3 8.785E-3 1.526E-2 2 10
14 ctd:C107875 6-(methylamino)pyrido(3,4-d)pyrimidine CTD 4.824E-6 1.017E-3 8.785E-3 1.526E-2 2 10
15 CID000002427 BPIQ-I Stitch 4.824E-6 1.017E-3 8.785E-3 1.526E-2 2 10
16 CID000001697 4,5-dianilinophthalimide Stitch 5.895E-6 1.097E-3 9.472E-3 1.864E-2 2 11
17 CID005311105 BE-23372M Stitch 5.895E-6 1.097E-3 9.472E-3 1.864E-2 2 11
18 CID011809364 2nq6 Stitch 8.357E-6 1.323E-3 1.143E-2 2.643E-2 2 13
19 CID000446506 AC1L9JR2 Stitch 8.357E-6 1.323E-3 1.143E-2 2.643E-2 2 13
20 CID000072425 teleocidin B Stitch 8.367E-6 1.323E-3 1.143E-2 2.647E-2 3 123
21 ctd:C516714 NVP-TAE684 CTD 1.125E-5 1.617E-3 1.396E-2 3.557E-2 2 15
22 CID005494446 2aq7 Stitch 1.125E-5 1.617E-3 1.396E-2 3.557E-2 2 15
23 CID000058035 AC1L1O6Q Stitch 1.261E-5 1.626E-3 1.404E-2 3.988E-2 3 141
24 CID000324081 4-anilinoquinazoline Stitch 1.285E-5 1.626E-3 1.404E-2 4.064E-2 2 16
25 CID000008010 propanedinitrile Stitch 1.285E-5 1.626E-3 1.404E-2 4.064E-2 2 16
26 CID001367558 AB-4 Stitch 1.830E-5 2.067E-3 1.786E-2
5.789E-2
 2 19
27 ctd:C076715 pervanadate CTD 1.830E-5 2.067E-3 1.786E-2
5.789E-2
 2 19
28 CID000011495 3,4-d Stitch 1.830E-5 2.067E-3 1.786E-2
5.789E-2
 2 19
29 CID000541551 N1-aminopropylagmatine Stitch 2.471E-5 2.605E-3 2.250E-2
7.816E-2
 2 22
30 CID000010089 phenadoxone Stitch 2.471E-5 2.605E-3 2.250E-2
7.816E-2
 2 22
31 CID000005060 tyrphostin RG13022 Stitch 3.207E-5 2.940E-3 2.539E-2
1.014E-1
 2 25
32 CID006857413 AC1OAGKW Stitch 3.224E-5 2.940E-3 2.539E-2
1.020E-1
 3 193
33 4491 DN Althiazide [5588-16-9]; Down 200; 10.4uM; PC3; HT HG-U133A Broad Institute CMAP Down 3.376E-5 2.940E-3 2.539E-2
1.068E-1
 3 196
34 3204 UP Practolol [6673-35-4]; Up 200; 15uM; MCF7; HT HG-U133A Broad Institute CMAP Up 3.376E-5 2.940E-3 2.539E-2
1.068E-1
 3 196
35 CID006918508 BIBX1382BS Stitch 3.474E-5 2.940E-3 2.539E-2
1.099E-1
 2 26
36 6517 DN Articaine hydrochloride [23964-57-0]; Down 200; 12.4uM; MCF7; HT HG-U133A Broad Institute CMAP Down 3.480E-5 2.940E-3 2.539E-2
1.101E-1
 3 198
37 2476 UP Propylthiouracil [51-52-5]; Up 200; 23.4uM; HL60; HT HG-U133A Broad Institute CMAP Up 3.532E-5 2.940E-3 2.539E-2
1.117E-1
 3 199
38 6357 UP Condelphine [7633-69-4]; Up 200; 8.8uM; PC3; HT HG-U133A Broad Institute CMAP Up 3.532E-5 2.940E-3 2.539E-2
1.117E-1
 3 199
39 CID000133027 DAPH1 Stitch 3.751E-5 3.042E-3 2.628E-2
1.187E-1
 2 27
40 CID000017608 benzylidenemalononitrile Stitch 4.039E-5 3.116E-3 2.691E-2
1.278E-1
 2 28
41 CID000129920 JS-1 Stitch 4.039E-5 3.116E-3 2.691E-2
1.278E-1
 2 28
42 ctd:C408604 PD 169316 CTD 4.338E-5 3.267E-3 2.821E-2
1.372E-1
 2 29
43 CID000122127 Rc-3095 Stitch 4.647E-5 3.340E-3 2.885E-2
1.470E-1
 2 30
44 CID000449200 1 x OE Stitch 4.647E-5 3.340E-3 2.885E-2
1.470E-1
 2 30
45 CID006419759 K00077 Stitch 4.828E-5 3.394E-3 2.931E-2
1.527E-1
 3 221
46 CID000002059 IN1434 Stitch 4.966E-5 3.415E-3 2.949E-2
1.571E-1
 2 31
47 CID000004713 PD98059 Stitch 5.651E-5 3.803E-3 3.284E-2
1.787E-1
 3 233
48 CID000005612 AC1L1KQK Stitch 6.722E-5 4.430E-3 3.826E-2
2.126E-1
 2 36
49 CID000011510 N-hydroxyurethane Stitch 7.105E-5 4.587E-3 3.961E-2
2.247E-1
 2 37
50 CID000123631 gefitinib Stitch 7.389E-5 4.674E-3 4.037E-2
2.337E-1
 3 255
Show 45 more annotations

18: Disease [Display Chart] 8 input genes in category / 978 annotations before applied cutoff / 16205 genes in category

ID Name Source pValue FDR B&H FDR B&Y Bonferroni Genes from Input Genes in Annotation
1 C0334254 Lymphoepithelial carcinoma DisGeNET BeFree 1.301E-8 1.272E-5 9.493E-5 1.272E-5 3 11
2 C0235593 Thoracic lymphadenopathy DisGeNET BeFree 2.133E-7 1.043E-4 7.783E-4 2.086E-4 2 2
3 C1708781 Lung Sarcomatoid Carcinoma DisGeNET BeFree 6.396E-7 2.085E-4 1.556E-3 6.256E-4 2 3
4 C0085281 Addictive Behavior DisGeNET BeFree 1.739E-6 4.168E-4 3.111E-3 1.701E-3 4 207
5 C0334233 Pleomorphic carcinoma DisGeNET BeFree 2.131E-6 4.168E-4 3.111E-3 2.084E-3 2 5
6 C0279682 Bladder Adenocarcinoma DisGeNET BeFree 5.963E-6 6.479E-4 4.836E-3 5.831E-3 2 8
7 C1851584 Familial ependymoma DisGeNET BeFree 5.963E-6 6.479E-4 4.836E-3 5.831E-3 2 8
8 C0220654 Meningeal Carcinomatosis DisGeNET BeFree 5.963E-6 6.479E-4 4.836E-3 5.831E-3 2 8
9 C0334246 Squamous cell carcinoma, metastatic DisGeNET BeFree 5.963E-6 6.479E-4 4.836E-3 5.831E-3 2 8
10 C0279557 Adenosquamous cell lung cancer DisGeNET BeFree 7.664E-6 7.299E-4 5.447E-3 7.496E-3 2 9
11 C0035369 Retroviridae Infections DisGeNET BeFree 8.209E-6 7.299E-4 5.447E-3 8.029E-3 3 87
12 C0206629 Pulmonary Blastoma DisGeNET BeFree 9.578E-6 7.797E-4 5.819E-3 9.367E-3 2 10
13 C0007130 Mucinous Adenocarcinoma DisGeNET Curated 1.036E-5 7.797E-4 5.819E-3 1.014E-2 3 94
14 C0278601 Inflammatory Breast Carcinoma DisGeNET Curated 1.139E-5 7.959E-4 5.940E-3 1.114E-2 3 97
15 C0553580 Ewings sarcoma DisGeNET Curated 1.430E-5 8.803E-4 6.570E-3 1.399E-2 4 352
16 C0007138 Carcinoma, Transitional Cell DisGeNET Curated 1.529E-5 8.803E-4 6.570E-3 1.495E-2 4 358
17 C0007129 Merkel cell carcinoma DisGeNET Curated 1.530E-5 8.803E-4 6.570E-3 1.496E-2 3 107
18 C1266002 Non-small cell carcinoma DisGeNET BeFree 1.659E-5 9.014E-4 6.727E-3 1.622E-2 2 13
19 C0262584 Carcinoma, Small Cell DisGeNET Curated 1.851E-5 9.526E-4 7.110E-3 1.810E-2 3 114
20 C0265783 Congenital hypoplasia of lung DisGeNET Curated 2.052E-5 1.004E-3 7.490E-3 2.007E-2 3 118
21 C0206062 Lung Diseases, Interstitial DisGeNET Curated 2.158E-5 1.005E-3 7.502E-3 2.111E-2 3 120
22 C0016978 gallbladder neoplasm DisGeNET Curated 2.550E-5 1.134E-3 8.461E-3 2.494E-2 2 16
23 C1145670 Respiratory Failure DisGeNET Curated 2.872E-5 1.175E-3 8.770E-3 2.808E-2 3 132
24 C0854988 Adenocarcinoma of lung, stage IV DisGeNET BeFree 2.890E-5 1.175E-3 8.770E-3 2.826E-2 2 17
25 C1337013 Differentiated Thyroid Gland Carcinoma DisGeNET BeFree 3.004E-5 1.175E-3 8.770E-3 2.938E-2 3 134
26 C1321546 Anaplastic large B-cell lymphoma DisGeNET BeFree 3.250E-5 1.223E-3 9.124E-3 3.179E-2 2 18
27 C0686377 CNS metastases DisGeNET BeFree 3.632E-5 1.315E-3 9.817E-3 3.552E-2 2 19
28 C0007115 Malignant neoplasm of thyroid DisGeNET BeFree 4.841E-5 1.657E-3 1.237E-2 4.734E-2 4 480
29 C0220650 Metastatic malignant neoplasm to brain DisGeNET BeFree 4.913E-5 1.657E-3 1.237E-2 4.805E-2 3 158
30 C3539781 Progressive cGVHD DisGeNET BeFree 5.591E-5 1.764E-3 1.316E-2
5.468E-2
 3 165
31 C0677932 Progressive Neoplastic Disease DisGeNET BeFree 5.591E-5 1.764E-3 1.316E-2
5.468E-2
 3 165
32 C0346109 Malignant Mesothelioma of Peritoneum DisGeNET BeFree 5.854E-5 1.780E-3 1.328E-2
5.725E-2
 2 24
33 C1861305 TARSAL-CARPAL COALITION SYNDROME DisGeNET Curated 6.005E-5 1.780E-3 1.328E-2
5.873E-2
 3 169
34 C0677936 Refractory cancer DisGeNET BeFree 6.438E-5 1.852E-3 1.382E-2
6.296E-2
 3 173
35 C0205697 Carcinoma, Spindle-Cell DisGeNET BeFree 6.890E-5 1.852E-3 1.382E-2
6.739E-2
 2 26
36 C1319315 Adenocarcinoma of large intestine DisGeNET BeFree 7.008E-5 1.852E-3 1.382E-2
6.854E-2
 3 178
37 C0238461 Anaplastic thyroid carcinoma DisGeNET Curated 7.008E-5 1.852E-3 1.382E-2
6.854E-2
 3 178
38 C0027831 Neurofibromatosis 1 DisGeNET Curated 7.610E-5 1.936E-3 1.445E-2
7.442E-2
 3 183
39 C2931618 Gestational trophoblastic disease DisGeNET Curated 8.010E-5 1.936E-3 1.445E-2
7.834E-2
 2 28
40 C1279945 Acute interstitial pneumonia DisGeNET BeFree 8.010E-5 1.936E-3 1.445E-2
7.834E-2
 2 28
41 C0948380 Colorectal cancer metastatic DisGeNET BeFree 8.115E-5 1.936E-3 1.445E-2
7.937E-2
 3 187
42 C0027643 Neoplasm Recurrence, Local DisGeNET Curated 1.050E-4 2.445E-3 1.825E-2
1.027E-1
 2 32
43 C0346976 Secondary malignant neoplasm of pancreas DisGeNET BeFree 1.117E-4 2.484E-3 1.854E-2
1.093E-1
 2 33
44 C1402294 Primary Lesion DisGeNET BeFree 1.117E-4 2.484E-3 1.854E-2
1.093E-1
 2 33
45 C0023440 Acute Erythroblastic Leukemia DisGeNET Curated 1.314E-4 2.833E-3 2.114E-2
1.286E-1
 3 220
46 C1332460 Barrett's Adenocarcinoma DisGeNET BeFree 1.332E-4 2.833E-3 2.114E-2
1.303E-1
 2 36
47 C0149978 Adenocarcinoma of rectum DisGeNET BeFree 1.408E-4 2.930E-3 2.187E-2
1.377E-1
 2 37
48 C0149678 Epstein-Barr Virus Infections DisGeNET BeFree 1.461E-4 2.966E-3 2.214E-2
1.429E-1
 3 228
49 C0152268 Hodgkin's disease, nodular sclerosis (clinical) DisGeNET BeFree 1.486E-4 2.966E-3 2.214E-2
1.453E-1
 2 38
50 C0278510 Medulloblastoma, Childhood DisGeNET BeFree 1.566E-4 3.063E-3 2.286E-2
1.531E-1
 2 39
Show 45 more annotations